SWM
PTPI

Spire Wealth Management’s Petros Pharmaceuticals PTPI Stock Holding History

Spire Wealth Management’s Portfolio PTPI Stock Details PTPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-176
Closed -$161K – 2887
2021
Q1 		$161K Buy
+176
New +$166K ﹤0.01% 1164

Other funds holding PTPI

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.2B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFAS
Acorn Financial Advisory Services Reston, Virginia $753M AUM 36.94% 1-Year Est. Return
PTP
Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spire Wealth Management's PTPI Position: Q2 2021 in Review

Spire Wealth Management sold out of Petros Pharmaceuticals (PTPI) in Q2 2021, closing a stake of 176 shares — an estimated $161K sold.

Spire Wealth Management first reported a position in PTPI in Q1 2021 and held it in 1 quarter. The position peaked at $161K in Q1 2021. 18 funds tracked by Wall St. Rank hold PTPI as of Q2 2021.

  • Spire Wealth Management reported no remaining Petros Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Spire Wealth Management sold 176 Petros Pharmaceuticals shares in Q2 2021, an estimated $161K.
  • Spire Wealth Management first reported a position in Petros Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Spire Wealth Management's Petros Pharmaceuticals position peaked at $161K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2021.

Based on Spire Wealth Management's 13F filing for Q2 2021, filed 26 Jul 2021.